- Protagonist Therapeutics (PTGX) exhibits strong technical momentum, posting a 150% gain over the past 52 weeks.
- PTGX holds a 100% “Buy” technical opinion from Barchart.
- Despite bullish analyst sentiment and price targets up to $137, I remain cautious due to low price stability, high short interest, and erratic earnings predictions.
- I am choosing to invest elsewhere, as PTGX’s high valuation, low growth, and speculative profile outweigh its recent momentum.